Immix Biopharma - NXC-201 gains Orphan Drug designation in MM
Immix has announced that the FDA has granted orphan drug designation (ODD) to CAR-T asset NXC-201 for multiple myeloma (MM). The benefits of ODD...
376 Views
Immix Biopharma - Progressing as expected on all fronts
Immix reported Q223 results, which were largely as expected. Operational highlights included rolling positive newsflow for CAR-T therapy NXC-201...
408 Views
Immix Biopharma - IMX-110 interim results in colorectal cancer
Immix has shared interim data from the Phase Ib/IIa trial evaluating IMX-110 in combination with tislelizumab for solid tumors. As of the data...
223 Views
Immix Biopharma - ATM completion may extend runway into H224
Immix Biopharma has completed its $5.0m at-the-market (ATM) offering program. The funding is as a result of the initial share sales agreement in...
340 Views
Immix Biopharma - A quarter focusing on a CAR-T strategy
Following recent updates regarding Immix’s CAR-T therapy (NXC-201) and Q123 results, we have adjusted our financial estimates. Quarterly R&D...
196 Views